Skip to content

Released Mar 5, 2021, before the open

10-K filed Mar 5, 2021, 64 days after period end · 0001564590-21-011110

Q4 2020 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$8.39MderivedN/M vs Q4 2019N/M vs Q3 2020
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$7,950,000N/M
Operating Cash Flowderived-$6,573,000N/M
Free Cash Flowderived-$6,656,000N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2020derived from reported figuresQ4 2019
Net Income-$8.39M-$11.68K
EPS Diluted—$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR